TrialBone marrow transplantation2021

Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation.

Marjan Cruijsen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.